Structural Basis for the Mutation-Induced Dysfunction of Human CYP2J2: A Computational Study

Arachidonic acid is an essential fatty acid in cells, acting as a key inflammatory intermediate in inflammatory reactions. In cardiac tissues, CYP2J2 can adopt arachidonic acid as a major substrate to produce epoxyeicosatrienoic acids (EETs), which can protect endothelial cells from ischemic or hypoxic injuries and have been implicated in the pathogenesis of coronary artery disease and hypertension. However, some CYP2J2 polymorphisms, i.e., T143A and N404Y, significantly reduce the metabolism of arachidonic acid. Lacking experimental structural data for CYP2J2, the detailed mechanism for the mutation-induced dysfunction in the metabolism of arachidonic acid is still unknown. In the current study, three-dimensional structural models of the wild-type CYP2J2 and two mutants (T143A and N404Y) were constructed by a coordinate reconstruction approach and ab initio modeling using CYP2R1 as a template. The structural analysis of the computational models showed that the wild-type CYP2J2 exhibited a typical CYP fold with 12 alpha-helices and three beta-sheets on one side and with the heme group buried deeply inside the core. Due to the small and hydrophobic side-chain, T143A mutation could destabilize the C helix, further placing the water access channel in a closed state to prevent the escape of the produced water molecules during the catalytic processes. N404Y mutation could reposition the side-chain of Leu(378), making it no longer form a hydrogen bond with the carboxyl group of arachidonic acid. However, this hydrogen bond was essential for substrate recognition and positioning in a correct orientation.

[1]  D. Mozaffarian,et al.  Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention , 2009, Circulation.

[2]  H. Sprecher.  Metabolism of highly unsaturated n-3 and n-6 fatty acids. , 2000, Biochimica et biophysica acta.

[3]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[4]  J. MacDonald,et al.  Phospholipid fatty acid remodeling in mammalian cells. , 1991, Biochimica et biophysica acta.

[5]  Sitao Wu,et al.  LOMETS: A local meta-threading-server for protein structure prediction , 2007, Nucleic acids research.

[6]  M. Waterman,et al.  Functional Variant of CYP4A11 20-Hydroxyeicosatetraenoic Acid Synthase Is Associated With Essential Hypertension , 2005, Circulation.

[7]  J. Ponder,et al.  Force fields for protein simulations. , 2003, Advances in protein chemistry.

[8]  I. Fleming.  Vascular cytochrome p450 enzymes: physiology and pathophysiology. , 2008, Trends in cardiovascular medicine.

[9]  A. Nasjletti,et al.  Differential Regulation of Natriuresis by 20-Hydroxyeicosatetraenoic Acid in Human Salt-Sensitive Versus Salt-Resistant Hypertension , 2003, Circulation.

[10]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[11]  Lourdes Santana,et al.  Medicinal chemistry and bioinformatics--current trends in drugs discovery with networks topological indices. , 2007, Current topics in medicinal chemistry.

[12]  S. Bandinelli,et al.  Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. , 2006, The Journal of clinical endocrinology and metabolism.

[13]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[14]  Tao Zhang,et al.  Advances in human cytochrome p450 and personalized medicine. , 2011, Current drug metabolism.

[15]  K. Tomer,et al.  Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (*) , 1996, The Journal of Biological Chemistry.

[16]  Ying Wang,et al.  Molecular Dynamics Studies on T1 Lipase: Insight into a Double-Flap Mechanism , 2010, J. Chem. Inf. Model..

[17]  J. Ping,et al.  Computational Studies on the Substrate Interactions of Influenza A Virus PB2 Subunit , 2012, PloS one.

[18]  D. Zeldin.  Epoxygenase Pathways of Arachidonic Acid Metabolism* , 2001, The Journal of Biological Chemistry.

[19]  Kuo-Chen Chou,et al.  Drug candidates from traditional chinese medicines. , 2008, Current topics in medicinal chemistry.

[20]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[21]  T. A. Jones,et al.  Using known substructures in protein model building and crystallography. , 1986, The EMBO journal.

[22]  Sason Shaik,et al.  The elusive oxidant species of cytochrome P450 enzymes: characterization by combined quantum mechanical/molecular mechanical (QM/MM) calculations. , 2002, Journal of the American Chemical Society.

[23]  Kuo-Chen Chou,et al.  Structure of cytochrome p450s and personalized drug. , 2009, Current medicinal chemistry.

[24]  Luhua Lai,et al.  Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..

[25]  Kuo-Chen Chou,et al.  Insights from modeling the 3D structure of NAD(P)H-dependent D-xylose reductase of Pichia stipitis and its binding interactions with NAD and NADP. , 2007, Biochemical and biophysical research communications.

[26]  Lourdes Santana,et al.  Proteomics, networks and connectivity indices , 2008, Proteomics.

[27]  Kuo-Chen Chou,et al.  3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. , 2007, Biochemical and biophysical research communications.

[28]  K. Lindpaintner,et al.  Risk of Coronary Artery Disease Associated With Polymorphism of the Cytochrome P450 Epoxygenase CYP2J2 , 2004, Circulation.

[29]  Paul Labute,et al.  The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area , 2008, J. Comput. Chem..

[30]  Hee-Won Park,et al.  Structural analysis of CYP2R1 in complex with vitamin D3. , 2007, Journal of molecular biology.

[31]  J. Skolnick,et al.  Ab initio modeling of small proteins by iterative TASSER simulations , 2007, BMC Biology.

[32]  H. Mohrenweiser,et al.  Cloning of CYP2J2 gene and identification of functional polymorphisms. , 2002, Molecular pharmacology.

[33]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[34]  Kuo-Chen Chou,et al.  Pharmacogenomics and personalized use of drugs. , 2008, Current topics in medicinal chemistry.

[35]  Kuo-Chen Chou,et al.  Insights from Modeling the 3D Structure of New Delhi Metallo-β-Lactamse and Its Binding Interactions with Antibiotic Drugs , 2011, PloS one.

[36]  T. L. Blundell,et al.  Knowledge-based prediction of protein structures and the design of novel molecules , 1987, Nature.

[37]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[38]  D. Zeldin,et al.  Up-Regulation of Endothelial Nitric-Oxide Synthase by Endothelium-Derived Hyperpolarizing Factor Involves Mitogen-Activated Protein Kinase and Protein Kinase C Signaling Pathways , 2003, Journal of Pharmacology and Experimental Therapeutics.

[39]  Sason Shaik,et al.  Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. , 2004, Chemical reviews.

[40]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[41]  Kuo-Chen Chou,et al.  Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. , 2008, Protein and peptide letters.

[42]  D S Moss,et al.  Main-chain bond lengths and bond angles in protein structures. , 1993, Journal of molecular biology.

[43]  A. A. Spector,et al.  Arachidonic acid cytochrome P450 epoxygenase pathway Work from my laboratory cited in this review was supported by National Institutes of Health grants HL049264 and HL072845. Published, JLR Papers in Press, October 23, 2008. , 2009, Journal of Lipid Research.

[44]  Urban Bren,et al.  Individual degrees of freedom and the solvation properties of water. , 2012, The Journal of chemical physics.

[45]  Kuo-Chen Chou,et al.  An Allosteric Mechanism Inferred from Molecular Dynamics Simulations on Phospholamban Pentamer in Lipid Membranes , 2011, PloS one.

[46]  Kuo-Chen Chou,et al.  Insights from studying the mutation-induced allostery in the M2 proton channel by molecular dynamics. , 2010, Protein engineering, design & selection : PEDS.

[47]  J. Liao,et al.  Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. , 2005, Archives of biochemistry and biophysics.

[48]  Jing-Fang Wang,et al.  A Negative Cooperativity Mechanism of Human CYP2E1 Inferred from Molecular Dynamics Simulations and Free Energy Calculations , 2011, J. Chem. Inf. Model..

[49]  T. Šolmajer,et al.  Binding free energy calculations of N-sulphonyl-glutamic acid inhibitors of MurD ligase , 2009, Journal of molecular modeling.

[50]  B. Nilius,et al.  Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. , 2008, Cardiovascular research.

[51]  Barry Honig,et al.  Extending the Applicability of the Nonlinear Poisson−Boltzmann Equation: Multiple Dielectric Constants and Multivalent Ions† , 2001 .

[52]  Pascal Benkert,et al.  QMEAN: A comprehensive scoring function for model quality assessment , 2008, Proteins.

[53]  Chris Oostenbrink,et al.  Cytochrome P450 3A4 Inhibition by Ketoconazole: Tackling the Problem of Ligand Cooperativity Using Molecular Dynamics Simulations and Free-Energy Calculations , 2012, J. Chem. Inf. Model..

[54]  Kuo-Chen Chou,et al.  Molecular modeling of cytochrome P450 and drug metabolism. , 2010, Current drug metabolism.

[55]  Ying Wang,et al.  Autoinhibitory Mechanism for the Mutation-Induced Impaired FGF9 Signaling , 2012, J. Chem. Inf. Model..

[56]  Joëlle Quetin-Leclercq,et al.  NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum. , 2011, Journal of theoretical biology.

[57]  Pomila Singh,et al.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases , 2009, Drugs of the Future.

[58]  Cristian R. Munteanu,et al.  MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. , 2011, Journal of proteome research.